The way I see it is that there are the current flexibilities on one end of the spectrum, and a waiver is basically saying, let's completely do away with copyright, patents, industrial designs and trade secrets, which is a very big carve-out from TRIPS.
The existing flexibilities may work, if potential manufacturers who meet all of the capacity requirements are able to comply with those flexibilities: if they are able to identify the need, understand exactly what they are going to need to make and ensure that they take all the steps needed to ensure that those vaccines are properly identified and not re-exported anywhere else. If they meet the TRIPS requirements and are able to do these things, then the TRIPS flexibility is enough.
If, on the other hand—